Researchers at the University of Cambridge have developed a new type of vaccine using artificial intelligence, a breakthrough they believe could help protect against entire families of viruses and strengthen global preparedness for future pandemics.
The study marks the first time that the key component of a vaccine has been designed entirely by artificial intelligence and then tested in human volunteers. Scientists say the technology could transform the way vaccines are developed, shifting the focus from reacting to outbreaks to preventing them before they occur.
The experimental vaccine was designed to provide protection against a broad range of coronaviruses, including existing Covid-19 variants as well as animal-borne coronaviruses that could potentially trigger future outbreaks.
According to Prof Jonathan Heeney of the University of Cambridge, the goal is to stay ahead of rapidly evolving viruses rather than constantly updating vaccines after new variants emerge.
Traditional vaccines are typically developed using a specific virus strain that is already circulating. However, viruses such as influenza and coronavirus frequently mutate, reducing the effectiveness of existing vaccines and making regular updates necessary.
To address this challenge, the Cambridge team collected genetic information from multiple coronaviruses identified through global surveillance programmes. Artificial intelligence then analysed the genetic data and designed what researchers call a "super-antigen" — a vaccine component intended to train the immune system to recognise and respond to a wider group of related viruses, including those that may emerge in the future.
Antigens are the parts of a vaccine that teach the immune system what to attack. By creating a broader antigen, researchers hope to provide protection that extends beyond a single virus strain.
Findings published in the Journal of Infection showed that the vaccine generated a measurable, though modest, immune response. Researchers stress that the work remains in its early stages, but they view the results as encouraging.
A larger follow-up trial involving approximately 200 participants is now underway to better understand the vaccine's effectiveness and immune response.
Prof Saul Faust of the University of Southampton, who was involved in conducting some of the clinical trials, described the technology as promising and particularly valuable for dealing with viruses that evolve rapidly.
He noted that AI-driven vaccine design could offer significant advantages when preparing for potential pandemics caused by emerging viral threats.
The Cambridge researchers are already applying the same technology to develop additional vaccines. Ongoing studies include efforts to create a universal seasonal influenza vaccine that would not require annual reformulation, as well as a vaccine targeting H5N1 bird flu, which continues to raise concerns among public health experts.
Prof Andy Pollard, Director of the Oxford Vaccine Group, said the research is generating compelling evidence and highlighted the growing role artificial intelligence could play in accelerating vaccine development.
While he cautioned that human immune systems are more complex than those of laboratory animals, he described the results as fascinating and said AI could become a major tool in future vaccine research.
Prof Marian Knight, Scientific Director at the National Institute for Health and Care Research, called the study an important milestone, saying the trial demonstrated the potential for broader and longer-lasting protection against viral diseases.
If successful, the approach could represent one of the most significant advances in vaccine development since the start of the Covid-19 pandemic, offering a new strategy for preventing outbreaks rather than simply responding to them.
